利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.071 秒)

    DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof
    1.
    发明申请
    DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129, and INTEGRIN ALPHA SUBUNIT Protein and nucleic acid molecules and uses thereof 有权
    DELTA3，FTHMA-070，TANGO85，TANGO77，SPOIL，NEOKINE，TANGO129和INTEGRIN ALPHA SUBUNIT蛋白质和核酸分子及其用途

    公开(公告)号：US20090286956A1

    公开(公告)日：2009-11-19

    申请号：US11974478

    申请日：2007-10-12

    申请人： Sean A. McCarthy ,  David P. Gearing ,  Douglas A. Holtzman ,  Yang Pan ,  Samantha J. Busfield ,  Thomas M. Barnes ,  Charles R. Mackay ,  Jose M. Lora

    发明人： Sean A. McCarthy ,  David P. Gearing ,  Douglas A. Holtzman ,  Yang Pan ,  Samantha J. Busfield ,  Thomas M. Barnes ,  Charles R. Mackay ,  Jose M. Lora

    IPC分类号： C07K14/705

    CPC分类号： C12Q1/48 ,  A61K38/00 ,  C07K14/47 ,  C07K2319/00 ,  C12Q1/6876

    摘要： The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供新颖的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259多肽，蛋白质和核酸分子。 除了分离的全长Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259蛋白外，本发明还提供了分离的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259融合 蛋白质，抗原肽和抗Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259抗体。 本发明还提供了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259核酸分子，含有本发明的核酸分子的重组表达载体，已经引入表达载体的宿主细胞， 已经引入或破坏了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129或A259基因的人类转基因动物。 还提供利用本发明组合物的诊断，筛选和治疗方法。

    DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
    2.
    发明申请
    DELTA3, FTHMA-070, TANGO85, TANGO77, SPOIL, NEOKINE, TANGO129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof 审中-公开
    DELTA3，FTHMA-070，TANGO85，TANGO77，SPOIL，NEOKINE，TANGO129和整合素α亚基蛋白和核酸分子及其用途

    公开(公告)号：US20080220495A1

    公开(公告)日：2008-09-11

    申请号：US11974465

    申请日：2007-10-12

    申请人： Sean A. McCarthy ,  David P. Gearing ,  Douglas A. Holtzman ,  Yang Pan ,  Samantha J. Busfield ,  Thomas M. Barnes ,  Charles R. Mackay ,  Jose M. Lora

    发明人： Sean A. McCarthy ,  David P. Gearing ,  Douglas A. Holtzman ,  Yang Pan ,  Samantha J. Busfield ,  Thomas M. Barnes ,  Charles R. Mackay ,  Jose M. Lora

    IPC分类号： C12N11/00 ,  C07K16/00 ,  C07K17/00

    CPC分类号： C12Q1/48 ,  A61K38/00 ,  C07K14/47 ,  C07K2319/00 ,  C12Q1/6876

    摘要： The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译： 本发明提供新颖的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259多肽，蛋白质和核酸分子。 除了分离的全长Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259蛋白外，本发明还提供了分离的Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259融合 蛋白质，抗原肽和抗Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259抗体。 本发明还提供了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129和A259核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞， 已经引入或破坏了Delta3，FTHMA-070，Tango85，Tango77，SPOIL，NEOKINE，Tango129或A259基因的人类转基因动物。 还提供利用本发明组合物的诊断，筛选和治疗方法。

    Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody
    7.
    发明申请
    Method of inhibiting leukocytes with human cxc chemokine receptor 3 antibody 审中-公开
    用人cxc趋化因子受体3抗体抑制白细胞的方法

    公开(公告)号：US20100061983A1

    公开(公告)日：2010-03-11

    申请号：US11903330

    申请日：2007-09-21

    申请人： Marcel Loetscher ,  Bernhard Moser ,  Shixin Qin ,  Charles R. Mackay

    发明人： Marcel Loetscher ,  Bernhard Moser ,  Shixin Qin ,  Charles R. Mackay

    IPC分类号： A61K39/395 ,  C07H21/02 ,  G01N33/53

    CPC分类号： C07K14/7158 ,  A61K38/00 ,  A61K47/642

    摘要： The present invention relates to proteins or polypeptides, referred to herein as isolated and/Or recombinant mammalian (e.g., human) IP-10/Mig receptor proteins designated CXC Chemokine Receptor 3 (CXCR3) and variants thereof, including those characterized by selective binding of one or more chemokines (e.g., IP-10 and/or Mig), and/or the ability to induce a cellular response (e.g., chemotaxis, exocytosis). Antibodies reactive with CXCR3 receptors can be produced using the proteins or variants thereof or host cells comprising same as immunogen.

    摘要翻译： 本发明涉及称为CXC趋化因子受体3（CXCR3）及其变体的分离和/或重组哺乳动物（例如人）IP-10 / Mig受体蛋白质的蛋白质或多肽，包括特征在于选择性结合 一种或多种趋化因子（例如，IP-10和/或Mig）和/或诱导细胞反应的能力（例如，趋化性，胞吐作用）。 可以使用蛋白质或其变体或包含免疫原的宿主细胞产生与CXCR3受体反应的抗体。

    Anti-CCR5 antibodies and kits comprising same
    9.
    发明授权
    Anti-CCR5 antibodies and kits comprising same 失效
    抗CCR5抗体和包含其的试剂盒

    公开(公告)号：US06528625B1

    公开(公告)日：2003-03-04

    申请号：US08893911

    申请日：1997-07-11

    申请人： Lijun Wu ,  Charles R. Mackay

    发明人： Lijun Wu ,  Charles R. Mackay

    IPC分类号： C07K1628

    CPC分类号： C07K16/2866 ,  A61K38/00 ,  Y10S435/81 ,  Y10S530/866

    摘要： The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR5 with a ligand thereof. Another aspect of the invention relates to a method of inhibiting HIV infection of a cell which expresses a mammalian CCR5 or portion thereof using the antibodies described herein. Also encompassed by the present invention are methods of treating or preventing HIV in a patient.

    摘要翻译： 本发明涉及与哺乳动物（例如人）趋化因子受体5蛋白（CKR-5或CCR5）或受体的一部分结合的抗体或其功能部分。 本发明还涉及抑制携带哺乳动物CCR5的细胞与其配体的相互作用的方法。 本发明的另一方面涉及使用本文所述的抗体抑制表达哺乳动物CCR5或其部分的细胞的HIV感染的方法。 本发明还包括在患者体内治疗或预防HIV的方法。

    Chemokine receptor antagonists and methods of use therefor
    10.
    发明授权
    Chemokine receptor antagonists and methods of use therefor 失效
    趋化因子受体拮抗剂及其使用方法

    公开(公告)号：US06323206B1

    公开(公告)日：2001-11-27

    申请号：US09010321

    申请日：1998-01-21

    申请人： Charles F. Schwender ,  Charles R. Mackay ,  Julia C. Pinto ,  Walter Newman

    发明人： Charles F. Schwender ,  Charles R. Mackay ,  Julia C. Pinto ,  Walter Newman

    IPC分类号： A61K314433

    CPC分类号： C07D405/06 ,  A61K31/05 ,  A61K31/137 ,  A61K31/14 ,  A61K31/216 ,  A61K31/222 ,  A61K31/404 ,  A61K31/423 ,  A61K31/428 ,  A61K31/451 ,  A61K31/4535 ,  A61K31/454 ,  A61K31/495 ,  A61K31/496 ,  C07D211/52 ,  C07D409/06 ,  C07D493/04

    摘要： Disclosed is a method of treating a subject with a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to the subject a therapeutically effective amount of a compound represented by the following structural formula: and physiologically acceptable salts thereof. Z is a cycloalkyl or non-aromatic heterocyclic ring group fused to one or more carbocyclic aromatic rings and/or heteroaromatic rings, wherein each ring in Z is independently substituted or unsubstituted; Y is a covalent bond, —O— or —CO—; n is an integer from one to about five; X is a covalent bond or —CO—; and M is >NR2, >CR1R2; R1 is —H, —OH, an aliphatic group, —O—(aliphatic group), —SH or —S—(aliphatic group); R2 is an aliphatic group, a substituted aliphatic group, an aromatic group, a substituted aromatic group, a benzylic group, a substituted benzylic group, a non-aromatic heterocyclic group or a substituted non-aromatic heterocyclic group.

    摘要翻译： 公开了一种用异常白细胞募集和/或激活相关疾病治疗受试者的方法。 该方法包括向受试者施用治疗有效量的由以下结构式表示的化合物：及其生理上可接受的盐.Z是与一个或多个碳环芳族环和/或杂芳族稠合的环烷基或非芳族杂环基 环，其中Z中的每个环独立地为取代或未取代的; Y为共价键，-O-或-CO-; n为1至约5的整数; X为共价键或-CO-; 并且M是> NR 2，> CR 1 R 2; R 1是-H，-OH，脂族基，-O-（脂族基），-SH或-S-（脂族基）; R 2是脂族基团，取代脂族基， 芳香族基团，取代芳香族基团，苄基基团，取代的苄基基团，非芳族杂环基团或取代的非芳族杂环基团。